- Home
- ACLS vs MIRM Comparison
ACLS vs MIRM Comparison
Compare ACLS & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLS
- MIRM
- Stock Information
- Founded
- ACLS 1995
- MIRM 2018
- Country
- ACLS United States
- MIRM United States
- Employees
- ACLS N/A
- MIRM N/A
- Industry
- ACLS Industrial Machinery/Components
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- ACLS Technology
- MIRM Health Care
- Exchange
- ACLS Nasdaq
- MIRM Nasdaq
- Market Cap
- ACLS 2.2B
- MIRM 2.5B
- IPO Year
- ACLS 2000
- MIRM 2019
- Fundamental
- Price
- ACLS $78.32
- MIRM $66.03
- Analyst Decision
- ACLS Buy
- MIRM Strong Buy
- Analyst Count
- ACLS 5
- MIRM 8
- Target Price
- ACLS $90.00
- MIRM $72.00
- AVG Volume (30 Days)
- ACLS 564.8K
- MIRM 465.6K
- Earning Date
- ACLS 08-05-2025
- MIRM 08-06-2025
- Dividend Yield
- ACLS N/A
- MIRM N/A
- EPS Growth
- ACLS N/A
- MIRM N/A
- EPS
- ACLS 4.91
- MIRM N/A
- Revenue
- ACLS $896,089,000.00
- MIRM $429,161,000.00
- Revenue This Year
- ACLS N/A
- MIRM $36.76
- Revenue Next Year
- ACLS $7.41
- MIRM $17.48
- P/E Ratio
- ACLS $16.18
- MIRM N/A
- Revenue Growth
- ACLS N/A
- MIRM 62.33
- 52 Week Low
- ACLS $40.40
- MIRM $36.86
- 52 Week High
- ACLS $117.57
- MIRM $61.00
- Technical
- Relative Strength Index (RSI)
- ACLS 62.21
- MIRM 81.46
- Support Level
- ACLS $74.88
- MIRM $50.25
- Resistance Level
- ACLS $80.48
- MIRM $61.00
- Average True Range (ATR)
- ACLS 3.22
- MIRM 2.10
- MACD
- ACLS 0.53
- MIRM 0.89
- Stochastic Oscillator
- ACLS 73.06
- MIRM 98.93
About ACLS Axcelis Technologies Inc.
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.